GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy

United States News News

GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy
United States Latest News,United States Headlines
  • 📰 Investingcom
  • ⏱ Reading Time:
  • 17 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 53%

GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy

- British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company's hepatitis B therapy.) initially developed and licensed to Janssen in 2018, will fuel the expansion of GSK's own hepatitis B treatment, bepirovirsen, it said.We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other.

{username} Just Now Share Follow this postUnfollow this post Save Saved. See Saved Items . This comment has already been saved in your Saved Items Author's response{commentContent} Reply 00 Report {username} Just NowAuthor's response Share Follow this postUnfollow this post Save Saved. See Saved Items .

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Investingcom /  🏆 450. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.Companies scheduled to report their results include Pfizer, GSK, Eli Lilly, and Novo Nordisk.
Read more »

Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer RSV vaccine lags GSK’s as head-to-head competition underway
Read more »

Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer (PFE.N), which dominated COVID vaccine sales, now finds itself looking up at GSK (GSK.L), whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer.
Read more »

How to report broken or hidden highway signs, maintenance issues across Bay Area: RoadshowHow to report broken or hidden highway signs, maintenance issues across Bay Area: RoadshowNeed to report broken or hidden highway signs, maintenance issues across Bay Area or anywhere else in California? Mr. Roadshow has you covered.
Read more »

7 Silent Signs You May be Iron Deficient7 Silent Signs You May be Iron DeficientDigital destination for sophisticated men & women. Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle.
Read more »

Does Strong Growth Fuel Inflation? Fed Debates Whether Old Model Still AppliesDoes Strong Growth Fuel Inflation? Fed Debates Whether Old Model Still AppliesOfficials look for signs that wages and prices are cooling even as spending, jobs remain robust
Read more »



Render Time: 2025-02-23 04:59:47